KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Moderna (MRNA) EBIAT (2017 - 2026)

Moderna (MRNA) has disclosed EBIAT for 10 consecutive years, with -$1.3 billion as the latest value for Q1 2026.

  • For Q1 2026, EBIAT fell 38.31% year-over-year to -$1.3 billion; the TTM value through Mar 2026 reached -$3.2 billion, up 4.86%, while the annual FY2025 figure was -$2.8 billion, 20.75% up from the prior year.
  • EBIAT hit -$1.3 billion in Q1 2026 for Moderna, down from -$826.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $3.7 billion in Q1 2022 and bottomed at -$3.6 billion in Q3 2023.
  • Average EBIAT over 5 years is -$239.9 million, with a median of -$825.0 million recorded in 2025.
  • Year-over-year, EBIAT surged 199.51% in 2022 and then plummeted 1638.46% in 2025.
  • Moderna's EBIAT stood at $1.5 billion in 2022, then tumbled by 85.19% to $217.0 million in 2023, then tumbled by 616.13% to -$1.1 billion in 2024, then grew by 26.25% to -$826.0 million in 2025, then plummeted by 62.59% to -$1.3 billion in 2026.
  • According to Business Quant data, EBIAT over the past three periods came in at -$1.3 billion, -$826.0 million, and -$200.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.